|Day Low/High||94.06 / 96.03|
|52 Wk Low/High||62.55 / 101.28|
The bifurcation can be seen just by looking at Apple's recent results.
Shares of AbbVie were up Friday after the company reported a big jump in revenue.
Consider raising your sell stop protection to a close below $61.
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
Valuations are stretched in certain names and industries, so some profit-taking appears in order.
These names are now oversold and are sitting at attractive prices.
Analysts cut valuation estimates after a disappointing drug study.
With the recent pullback in the stock price, AbbVie is an attractive buy.
Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.
Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.
This is because they would buy more of the winning stocks lower.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
The market is having a quiet day in front of the long holiday weekend. However, biotech is concluding another strong week, which makes two in a row. I'm noticing some small biotechs on the move today. Aratana Therapeutics (PETX) is up 7% today. Ther...
Keep cash on hand and be ready for oportunities as they arise.
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.
We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.
Home Depot shares were falling despite a strong first-quarter showing.
It is hard to see much growth in the market overall, until earnings growth returns.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
Larry Robbins, Carson Block and John Khoury hold court at the 2106 Sohn Conference.
The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss Wednesday.
The M&A activity is an incredible and a welcome sign.
This earnings season continues to disappoint, and technology names are leading the downward charge.
It's important to focus on hitting singles in this overbought and earnings-starved environment.
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.